Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: High Dose Candesartan for Proteinuria Reduction
NCT00242346Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2003
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan in diabetic nephropathy (DN), hypertensive nephrosclerosis (HN), proteinuria and 1 more (3 arms), sponsored by AstraZeneca. Primary endpoint: Reduction in proteinuria from baseline at 30 weeks. Started Apr 2003; status: completed.
02
Drugs
candesartan
03
Conditions
diabetic nephropathy (DN)hypertensive nephrosclerosis (HN)proteinuriahypertension (HTN)
Beyond the preview
Go deeper on NCT00242346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242346.